It’s only fair to share… Pexidartinib, New Patent, WO, 2017215521, Crystal Pharmatech Co Ltd (WO2017215521) PLX3397 HYDROCHLORIDE CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017215521 CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD INVENTORS CHEN, Minhua; (CN). ZHANG, Yanfeng; (CN). ZOU, Po; (CN). ZHANG, Xiaoyu; (CN) Novel crystalline forms of PLX3397 hydrochloride (designated as Forms CS2 and …
Tag «Pexidartinib»
Pexidartinib, PLX-3397
It’s only fair to share… Pexidartinib PLX-3397 5-((5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine N-[5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-3-pyridinemethanamine 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine hydrochloride Phase III A Multi-targeted tyrosine kinase inhibitor potentially for the treatment of tenosynovial giant cell tumor (TGCT). CAS 1029044-16-3 C20H15ClF3N5, 417.81 Pexidartinib; 1029044-16-3; PLX-3397; 5-((5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine; 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine; 5-[(5-Chloro-1h-Pyrrolo[2,3-B]pyridin-3-Yl)methyl]-N-{[6-(Trifluoromethyl)pyridin-3-Yl]methyl}pyridin-2-Amine; Originator Plexxikon Developer Barbara Ann Karmanos Cancer Institute; Columbia University; Merck & Co; National Cancer Institute (USA); Plexxikon; University …